SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

You may be eligible if

• Histologically confirmed adenocarcinoma of the prostate
• * Metastatic disease (N1 and/or M1)
• * Unresponsive or refractory to androgen-deprivation therapy
• Must have received one, and only one, prior taxane-containing (docetaxel or paclitaxel) chemotherapy regimen for metastatic disease that was discontinued due to disease progression, intolerance, or patient request
• Evidence of disease progression as defined by ≥ 1 of the following:
• * Progression of measurable disease
• * Progression of evaluable disease
• * Rising prostate-specific antigen (PSA)
• * At least 2 consecutive rises in PSA levels, each taken ≥ 7 days apart
• * PSA ≥ 5 ng/mL
• Must have pre-study PSA \> 5 ng/mL
• Measurable or evaluable disease
• * Soft tissue disease that has been irradiated within the past 2 months is not considered measurable disease
• * Soft tissue disease that has been irradiated ≥ 2 months prior to study entry is considered measurable disease provided the lesion progressed after radiation
• Surgical or medical castration required
• * If luteinizing hormone-releasing hormone (LHRH) agonists (leuprolide or goserelin) or LHRH antagonists (abarelix) were used, then must continue use during study therapy
• No prior or concurrent brain metastases (treated or untreated)
• * If clinical suspicion of brain metastases, must meet the following criteria:
• * Brain CT scan or MRI negative for metastatic disease within the past 56 days
• * No new symptoms since radiographic evaluation
• Performance status - Zubrod 0-2
• Absolute granulocyte count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 9 g/dL
• Bilirubin normal
• SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN)
• Creatinine ≤ 1.5 times ULN
• Creatinine clearance ≥ 40 mL/min
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Fertile patients must use effective contraception
• No peripheral neuropathy ≥ grade 2
• No prior allergic reaction attributed to compounds of similar chemical or biological composition to SB-715992
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study participation
• No other uncontrolled illness
• No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or adequately treated stage I or II cancer in complete remission
• No colony-stimulating factors during the first course of study therapy
• No concurrent anticancer biologic therapy
• See Disease Characteristics
• At least 4 weeks since prior chemotherapy and recovered
• See Disease Characteristics
• At least 4 weeks since prior flutamide or ketoconazole
• At least 6 weeks since prior bicalutamide or nilutamide
• No concurrent anticancer hormonal therapy except LHRH agonist or antagonist for patients who have not undergone orchiectomy
• See Disease Characteristics
• At least 4 weeks since prior radiotherapy and recovered
• Prior samarium Sm 153 lexidronam pentasodium allowed
• No prior strontium chloride Sr 89
• No prior radiotherapy to ≥ 30% of bone marrow
• No concurrent anticancer radiotherapy
• See Disease Characteristics
• At least 3 weeks since prior surgery and recovered
• At least 2 weeks since prior and no concurrent use of any of the following CYP3A4 inhibitors or inducers:
• * Clarithromycin
• * Erythromycin
• * Troleandomycin
• * Rifampin
• * Rifabutin
• * Rifapentine
• * Itraconazole
• * Ketoconazole
• * Fluconazole (dose \> 200 mg/day)
• * Voriconazole
• * Nefazodone
• * Fluvoxamine
• * Verapamil
• * Diltiazem
• * Grapefruit juice
• * Bitter orange
• * Phenytoin
• * Carbamazepine
• * Phenobarbital
• * Oxcarbazepine
• * Hypericum perforatum (St. John's wort)
• * Modafinil
• At least 6 months since prior and no concurrent amiodarone
• No other investigational drugs for 4 weeks before, during, and for 2 weeks after study therapy
• No other concurrent anticancer cytotoxic therapy
• No other concurrent anticancer therapy
• No concurrent combination antiretroviral therapy for HIV-positive patients
• Concurrent enrollment on SWOG-9205 (central prostate cancer serum repository protocol) allowed